[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100380995":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":38,"locations":48,"responsibleParty":64,"collaborators":42,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":69,"sex":75,"minAge":76,"maxAge":42,"enrollmentInfo":77,"targetDuration":42,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":51,"whyStopped":42,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Fu Wai Hospital, Beijing, China","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"LD group","EXPERIMENTAL","Low-dose Aspirin(50mg qd) + Ticagrelor( 90mg bid) for 12 months",[13,14],"Drug: Aspirin","Drug: Ticagrelor",{"label":16,"type":17,"description":18,"interventionNames":19},"Control group","ACTIVE_COMPARATOR","Regular Aspirin(75mg qd) + Ticagrelor(90mg bid) for 12 months",[13,14],[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Aspirin","Comparison of 12 months of ticagrelor and low-dose aspirin versus 12 months of standard dual anti-platelet therapy (DAPT)",[16,9],[27],"Acetylsalicylic Acid",{"type":22,"name":29,"description":24,"armGroupLabels":30,"otherNames":31},"Ticagrelor",[16,9],[32],"Brilinta\u002FBrilique",[34],{"name":35,"affiliation":36,"role":37},"Haiyan Qian, MD, PhD","Fuwai Hospital, Beijing, China","PRINCIPAL_INVESTIGATOR",[39,44],{"name":35,"role":40,"phone":41,"phoneExt":42,"email":43},"CONTACT","+8613811386143",null,"ahqhy712@163.com",{"name":45,"role":40,"phone":46,"phoneExt":42,"email":47},"Zhiyao Wei","+8615521192379","weizhiyaoyx@163.com",[49],{"facility":50,"status":51,"city":52,"state":53,"zip":42,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"Fuwai Hospital","RECRUITING","Beijing","Beijing Municipality","China","CN",{"type":57,"coordinates":58},"Point",[59,60],116.39723,39.9075,{"lat":60,"lon":59},[63],{"name":35,"role":40,"phone":41,"phoneExt":42,"email":43},{"type":37,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":42,"oldOrganization":42},"Qian Haiyan","MD, PhD","100380995","phase-4-ticagrelor-with-low-dose-versus-regular-aspirin-in-patients-with-acute-coronary-syndrome-acs-at-high-risk-for-ischemia-after-percutaneous-coronary-intervention-100380995",false,"NCT04240834","Ticagrelor With Low-dose Versus Regular Aspirin in Patients With Acute Coronary Syndrome (ACS) at High-Risk for Ischemia After Percutaneous Coronary Intervention","Safety and Efficacy of Ticagrelor With Low-dose Aspirin Versus Regular Aspirin in Patients With Acute Coronary Syndrome at High-risk for Ischemia After Percutaneous Coronary Intervention: A Randomized Controlled Study","LD-ASPIRIN","Inclusion Criteria:\n\n* ACS patients at high risk for ischemic events after successful PCI with implantation of at least one drug eluting stent\n* Able and willing to provide informed consent and participate in 12 months follow-up period\n* Able to receive DAPT treatment\n* Enrollment into the study will require meeting at least one angiographic or clinical inclusion and none of the exclusion criteria.\n\nClinical inclusion criteria:\n\n1. Family history of premature coronary heart disease (Coronary heart disease in first-degree male relative \\\u003C55 years old or in first-degree female relative \\\u003C65 years old)\n2. Repeated myocardial infarction\n3. Positive serum cardiac troponin I\u002FT\n4. Combined with at least one organ\u002Fsystem with atherosclerotic disease (e.g. intracranial or peripheral arteries)\n5. Type 2 diabetes mellitus under medication\n6. Chronic kidney disease (eGFR\\\u003C60 mL\u002Fmin\u002F1.73 m2 or CrCl\\\u003C60ml\u002Fmin)\n\nAngiographic Inclusion Criteria:\n\n1. LM lesion requiring stents\n2. Proximal LAD lesion(s) requiring stents\n3. Bypass grafts lesion(s) requiring stents\n4. Overall stent length ≥60 mm\n5. History of in-stent thrombosis\n6. Bifurcation lesions requiring at least 2 stents\n7. Over two vessels lesions requiring stents\n8. Calcified target lesion(s) requiring atherectomy\n9. The intraoperative occurrence of no-reflow or slow-flow\n10. Compressed branch vessels with a diameter of at least 2.0 mm failing to reach flow restoration (at least TIMI 3)\n\nExclusion Criteria:\n\n* Need for chronic oral anticoagulation\n* With cardiomyopathy（HCM\u002FDCM\u002FRCM）\n* With severe ventricular arrhythmia requiring ICD implantation\n* With chronic respiratory disease (COPD, asthma, chronic bronchitis, pulmonary heart disease)\n* With severe infectious disease（active hepatitis B, active hepatitis C, AIDS）\n* With hematological disorders（thrombocytopenia, severe anemia, leukaemia）\n* With severe liver disease or kidney failure\n* With malignant tumor\n* With cognitive impairment\n* Unable or unwilling to provide informed consent or undergo follow-up","ALL","18 Years",{"count":78,"type":79},1220,"ESTIMATED","INTERVENTIONAL",[82],"PHASE4","The present study is aimed to compare the safety and efficacy of Ticagrelor with low-dose Aspirin versus standard dual anti-platelet therapy (DAPT) in patients with acute coronary syndrome (ACS) at high risk for ischemic events after percutaneous coronary intervention (PCI) and stent implantation.",[85,86],"Acute Coronary Syndrome","Interventional Cardiology",[88,89,90,23,29],"ACS","PCI","DAPI","2024-06-15",{"date":93,"type":94},"2024-06-18","ACTUAL",{"date":96,"type":94},"2021-02-01",{"date":98,"type":79},"2026-12",{"name":5,"class":6},1]